Eurofins Announces AGM Agenda and Strengthens Balance Sheet Commitment

Eurofins Scientific SE has released the agenda for its Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) scheduled for April 24, 2025, in Luxembourg. Key items include the proposed appointment of Gavin Hill as an independent non-executive director, expanding the board's diversity. Hill, with experience in finance and industry, is expected to join the Audit and Risk, and Nomination and Remuneration Committees if appointed.

The agenda also includes a proposal for a consultative vote on Eurofins’ potential acquisition of 23 properties currently leased from Analytical Bioventures SCA. The transaction, estimated at €190 million, aims to optimize Eurofins' strategic asset ownership and reduce dependency on external landlords. This purchasing process could span over the next two to four years in tranches.

Eurofins emphasizes its strategic priority to maintain a strong balance sheet by managing leverage within the 1.5-2.5x range and intends to lower it towards the lower end by FY 2027.